RxDoctor Payments Data

Richard Shea, MD

Cardiovascular Disease · Indianapolis, INNPI 1578534004

Payments from drug & device makers

$16,491in general payments, 2019–2025

Across 125 payments — averaging $131.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$11K
  • Boston Scientific$4K
  • Medtronic$313
  • Abbott$242
  • Amgen$181
  • AstraZeneca$162
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$7,87548%
  • Grants$1891%
  • Travel & lodging$4,18325%
  • Food & beverage$4,23026%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,491 in reported general payments places this provider in the 75th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$131,711
Medicare patients
1,236
Services billed
2,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban296$383,097
XareltoRivaroxaban57$84,337
EntrestoSacubitril/Valsartan43$69,014
Repatha SureclickEvolocumab27$38,624
Metoprolol Succinate366$4,863
Atorvastatin Calcium371$3,521
Ezetimibe121$2,990
Diltiazem 12hr ErDiltiazem Hcl15$2,302
Nifedipine ErNifedipine58$2,194
Warfarin Sodium220$2,189
Losartan Potassium210$2,083
Amiodarone Hcl46$1,979
Diltiazem 24hr Er (Cd)Diltiazem Hcl65$1,785
Rosuvastatin Calcium132$1,781
Carvedilol205$1,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$383,097296 claims
Johnson & JohnsonXarelto$149$84,33757 claims
NovartisEntresto$79$69,01443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →